Neurocrine Closer To Ingrezza Label Expansion With Huntington’s Chorea Phase III Win

 
• By Joseph Haas
Brain research
Neurocrine thinks Ingrezza can better the competition in Huntington's chorea

More from Clinical Trials

More from R&D